

LIST OF TABLES

	Page	
Table I	Number of patients whose data were used for analyses in different chapters of Report No. 17	11
Table II	Distribution of prognostic stages in patients diagnosed in 2018	11
Table 1.1	Family history of breast cancer at diagnosis (N=20,104)	21
Table 1.2	Personal history of other tumours at diagnosis (N=20,104)	21
Table 1.3	Origins of malignant tumours reported by patients (N=361)	22
Table 1.4	History of benign breast disease at diagnosis (N=20,104)	22
Table 1.5	Menarche, menopause and reproductive history at diagnosis	23
Table 1.6	Number of live births reported by patients (N=15,180)	23
Table 1.7	Use of hormonal contraceptives at diagnosis (N=20,104)	24
Table 1.8	Use of hormone replacement therapy at diagnosis (N=10,692)	24
Table 1.9	Ten most common risk factors for breast cancer in patient cohort (N=20,104)	25
Table 1.10	Breast screening habits by age group	26
Table 1.11	Breast screening habits by education level	27
Table 1.12	Breast screening habits by monthly household income (HK\$)	28
Table 1.13	Breast screening habits by district of residence	29
Table 2.1	Methods of first breast cancer detection by type of medical service users (N=19,558)	34
Table 2.2	Methods of first breast cancer detection by type of cancer (N=19,377)	35
Table 2.3	Methods of first breast cancer detection by cancer stage (N=18,791)	35
Table 2.4	Time interval between onset of symptoms and first medical consultation for patients who self-detected their cancer by type of medical service users (N=4,586)	36
Table 2.5	Cancer stage at diagnosis among self-detected patients by time interval between onset of symptoms and first medical consultation (N=4,040)	37
Table 2.6	Laterality of breast cancer cases in the patient cohort (N=20,656)	37
Table 2.7	Sensitivity and diagnostic results of breast imaging tests (N=20,656)	38
Table 2.8	Mammographic findings of patients diagnosed through mammography (N=14,905)	39
Table 2.9	Mammographic density of breasts of patients diagnosed through mammography by age group (N=10,041)	39
Table 2.10	Sensitivity and diagnostic results of breast tissue biopsies (N=20,656)	40
Table 2.11	Method of cancer staging among invasive breast cancer patients (N=8,119)	41
Table 2.12	Histological type of invasive breast cancer (N=17,514)	44



	Page
Table 2.13 Grading, multifocality and multicentricity of invasive breast cancer (N=17,514)	44
Table 2.14 Biological characteristics of invasive breast cancer (N=17,514)	45
Table 2.15 Biological subtypes of invasive tumours by cancer stage (N=16,408)	46
Table 2.16 Histological type, grading, multifocality and multicentricity of in situ breast cancer (N=2,617)	47
Table 2.17 Biological characteristics of in situ breast cancer (N=2,617)	47
Table 2.18 Number of treatment modalities by cancer stage (N=19,821)	48
Table 2.19 Use of surgery for patients with invasive or in situ cancer	49
Table 2.20 Coverage of regional lymph nodes by adjuvant locoregional radiotherapy (N=7,702)	53
Table 2.21 Use of chemotherapy by age group and cancer stage at diagnosis (N=16,731)	54
Table 2.22 Follow-up of patients (N=18,872)	63
Table 2.23 Recurrence pattern of patients (N=18,092)	63
Table 2.24 Locoregional and distant recurrence among invasive breast cancer patients by cancer stage (N=15,467)	64
Table 2.25 Locoregional recurrence by type of surgery received and cancer stage at diagnosis	64
Table 2.26 Sites involved in locoregional recurrence (N=869)	65
Table 2.27 Sites involved in distant recurrence (N = 993)	65
Table 2.28 Time for organ-specific metastasis and distribution of the biological subtypes of patients	65
Table 2.29 Characteristics of breast cancer-specific deaths (N=1,708)	66
Table 3.1 Psychosocial impact of breast cancer	72
Table 3.2 Psychosocial adjustments and coping strategies for survivorship	73
Table 4.1 Ten most common risk factors for breast cancer in patient cohort (N=5,749)	77
Table 4.2 Breast screening habits	78
Table 4.3 Biological subtypes of invasive tumours by cancer stage (N=2,664)	80
Table 4.4 Number of treatment modalities by cancer stage (N=3,292)	81

LIST OF FIGURES

	Page	
Figure I	Distribution of year of diagnosis of HKBCR participants in the past 15 years	7
Figure 1.1	Distribution of age at diagnosis (N=20,104)	17
Figure 1.2	Occupation of patient cohort (N=20,104)	17
Figure 1.3	Education level of patient cohort (N=20,104)	18
Figure 1.4	Monthly household income (HK\$) of patient cohort (N=11,048)	18
Figure 1.5	District of residence of patient cohort (N=20,104)	18
Figure 1.6	Bra band size of patient cohort (N=15,579)	19
Figure 1.7	Bra cup size of patient cohort (N=13,125)	19
Figure 1.8	Dietary habits at diagnosis (N=20,104)	20
Figure 1.9	Exercise habits at diagnosis (N=20,104)	20
Figure 1.10	Stress level at diagnosis (N=20,104)	20
Figure 1.11	Body mass index at diagnosis (N=20,104)	21
Figure 1.12	Distribution of risk factors among patients at diagnosis (N=20,104)	25
Figure 2.1	Methods of first breast cancer detection in the patient cohort (N=19,558)	34
Figure 2.2	Major presenting symptoms of self-detected breast cancer in the patient cohort (N=16,086)	35
Figure 2.3	Time interval between onset of symptoms and first medical consultation for patients who self-detected their cancer (N=4,586)	36
Figure 2.4	Locations of malignant tumour on breasts within the patient cohort (N=20,656)	38
Figure 2.5	Mammographic density of breasts of patients diagnosed through mammography (N=10,262)	39
Figure 2.6	Use of PET scan among patients who had cancer staging by cancer stage (N=8,119)	41
Figure 2.7	Cancer stage at diagnosis (N=20,656)	42
Figure 2.8	Distribution of tumour size (cm) of invasive breast cancer (N=14,855)	42
Figure 2.9	Number of positive axillary lymph nodes among patients with invasive breast cancer (N=15,483)	43
Figure 2.10	Distribution of tumour size (cm) in invasive cancer with negative or positive nodal status (N=14,696)	43
Figure 2.11	Distribution of tumour size (cm) of in situ breast cancer (N=2,143)	43
Figure 2.12	Type of breast surgery by age group (N=19,691)	50
Figure 2.13	Type of breast surgery by invasive tumour size (cm) (N=15,991)	50
Figure 2.14	Type of breast surgery by cancer stage (N=19,525)	50
Figure 2.15	Type of breast surgery by type of medical service (N=19,454)	50
Figure 2.16	Type of nodal surgery by clinical nodal status (N=18,907)	51
Figure 2.17	Type of nodal surgery for invasive cancer by cancer stage (N=16,637)	51



	Page
Figure 2.18 Number of positive nodes by type of nodal surgery (N=17,000)	51
Figure 2.19 Use of radiotherapy among patients who underwent breast-conserving surgery by cancer stage (N=7,201)	52
Figure 2.20 Use of radiotherapy among patients who underwent mastectomy by cancer stage (N=11,970)	53
Figure 2.21 Use of chemotherapy by cancer stage (N=17,169)	54
Figure 2.22 Type of first generation chemotherapy regimens (non-HER2) used in neoadjuvant setting (N=163)	55
Figure 2.23 Type of second generation chemotherapy regimens (non-HER2) used in neoadjuvant setting (N=152)	55
Figure 2.24 Type of third generation chemotherapy regimens (non-HER2) used in neoadjuvant setting (N=587)	55
Figure 2.25 Type of HER2 regimens used in neoadjuvant setting (N=459)	55
Figure 2.26 Type of chemotherapy regimens used by biological subtype in neoadjuvant setting (N=1,315)	56
Figure 2.27 Type of first generation chemotherapy regimens (non-HER2) used in adjuvant setting (N=1,690)	57
Figure 2.28 Type of second generation chemotherapy regimens (non-HER2) used in adjuvant setting (N=2,718)	57
Figure 2.29 Type of third generation chemotherapy regimens (non-HER2) used in adjuvant setting (N=2,891)	57
Figure 2.30 Type of HER2 regimens used in adjuvant setting (N=914)	57
Figure 2.31 Type of chemotherapy regimens used by biological subtype in adjuvant setting (N=8,597)	58
Figure 2.32 Type of chemotherapy regimens used by cancer stage in adjuvant setting (N=8,682)	59
Figure 2.33 Type of chemotherapy regimens used by biological subtype in palliative setting (N=344)	60
Figure 2.34 Use of endocrine therapy by cancer stage (N=19,754)	61
Figure 2.35 Forms of endocrine therapy by age group (N=12,690)	61
Figure 2.36 Type of targeted therapy drugs used (N=3,018)	62
Figure 2.37 Use of anti-HER2 targeted therapy in HER2 positive patients by cancer stage (N=3,637)	62
Figure 2.38 Type of complementary and alternative therapies used (N=7,357)	63
Figure 3.1 Level of physical discomfort after surgery (N=18,229)	69
Figure 3.2 Level of physical discomfort by type of surgery (N=18,179)	69
Figure 3.3 Level of physical discomfort after radiotherapy (N=10,883)	70
Figure 3.4 Level of physical discomfort after radiotherapy by irradiated regions (N=7,230)	70
Figure 3.5 Level of physical discomfort after chemotherapy (N=10,714)	70
Figure 3.6 Level of physical discomfort after endocrine therapy (N=11,660)	70
Figure 3.7 Level of physical discomfort after targeted therapy (N=2,413)	71
Figure 3.8 Level of physical discomfort after complementary and alternative therapies (N=7,108)	71
Figure 3.9 Change in outlook on life by age group (N=17,539)	72
Figure 3.10 Change in self-image by age group (N=17,535)	73

	Page
Figure 3.11 Level of worry about recurrence by age group (N=17,537)	73
Figure 4.1 Distribution of age at diagnosis (N=5,749)	77
Figure 4.2 Education level of patient cohort (N=5,749)	77
Figure 4.3 Distribution of risk factors among patients at diagnosis (N=5,749)	77
Figure 4.4 Methods of first breast cancer detection in the patient cohort (N=3,460)	78
Figure 4.5 Time interval between onset of symptoms and first medical consultation for patients who self-detected their cancer (N=1,645)	78
Figure 4.6 Cancer stage at diagnosis (N=3,514)	79
Figure 4.7 Distribution of tumour size (cm) of invasive breast cancer (N=2,185)	79
Figure 4.8 Number of positive axillary lymph nodes among patients with invasive breast cancer (N=2,291)	79
Figure 4.9 Distribution of tumour size (cm) of in situ breast cancer (N=497)	80